Item 7.01. Regulation FD Disclosure.
Included as Exhibit 99.1 to this report is copy of a presentation that Lineage
Cell Therapeutics, Inc. (“Lineage”) intends to use in various meetings,
commencing on January 23, 2023, with investors, securities analysts and others.
The presentation, dated January 23, 2023 and incorporated herein by reference,
addresses, among other things, information about Lineage, its product candidates
and recent business developments.
The information contained in this Item 7.01, and in Exhibit 99.1 attached
hereto, is being “furnished” and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section 18 or of Sections
11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities
Act”). Furthermore, the information contained in this Item 7.01 and in Exhibit
99.1 shall not be deemed to be incorporated by reference into any registration
statement or other document filed by Lineage with the Securities and Exchange
Commission pursuant to the Securities Act or the Exchange Act, whether filed
before or after the date hereof, regardless of any general incorporation
language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Corporate Presentation dated January 23, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
-2-
© Edgar Online, source Glimpses
postbrexitcompliance.com 